- Home
- GDYN vs ALT Comparison
GDYN vs ALT Comparison
Compare GDYN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDYN | ALT |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.5M | 573.8M |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GDYN | ALT |
|---|---|---|
| Price | $7.64 | $3.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $10.67 | ★ $17.67 |
| AVG Volume (30 Days) | 858.5K | ★ 3.2M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 25.37 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $111,283,000.00 | $41,000.00 |
| Revenue This Year | $10.16 | N/A |
| Revenue Next Year | $10.84 | N/A |
| P/E Ratio | $385.00 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $5.11 | $2.56 |
| 52 Week High | $10.21 | $6.44 |
Technical Indicators
Market Signals| Indicator | GDYN | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 48.30 |
| Support Level | $7.61 | $2.80 |
| Resistance Level | $8.15 | $3.32 |
| Average True Range (ATR) | 0.25 | 0.13 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 17.75 | 5.00 |
Price Performance
Historical ComparisonAbout GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.